drugset / Trial / NCT01196260
Combination Chemotherapy Treatments in Patients With Colorectal Cancer Stage II and III
Phase 2/3
Unknown
8000 enrolled
State Key Laboratory of Cancer Biology
Beihua University · collabChengdu Medical College · collabShanghai Jiao Tong University School of Medicine · collabTianjin Union Medical Center · collab
RandomizedParallel-groupDouble-blindTreatment
Summary
This study will examine a new combination of drugs: Capecitabine and Oxaliplatin for the treatment of Stage II and III colorectal cancer. Capecitabine and Oxaliplatin are approved by the Food and Drug Administration (FDA) for use in colorectal cancer. The combination of drugs is experimental (not approved by the FDA as standard treatment), but is a widely used treatment option and preliminary studies have shown that treatment with the combination has a positive effect on metastatic colorectal cancer.
Timeline
- Start
- 2004-01
- Primary completion
- 2020-12
- Completion
- 2020-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Capecitabine | Small molecule | — | — |
| Subject | Oxaliplatin | Small molecule | — | — |